The significant co-occurrence of USF2 and CDK5 (p < 0.001) as well as the presence of genetic alterations in both genes (3.98% amplifications and 6.25% mutations in prostate adenocarcinoma/FHCRC study, and 3.21 % of amplifications in breast cancer/Metabric study) (cbioportal.org) together with the observed enhanced proliferation and migration of all cell lines expressing the phosphomimicking USF2 Ser155D/Ser222D but not the non-phosphorylatable USF2 Ser155A/Ser222A mutant favor the tumor-promoting role of USF2. Here, CDK5 is linked to prostate adenocarcinoma.